Editorial: evolution of GLP-1 receptor agonists as pharmacotherapy for NASH beyond diabetes mellitus and obesity – authors’ reply
Other text in scientific journal, 2021
Author
Anne Flint
Novo Nordisk
Grit Andersen
Profil
Paul Hockings
Chalmers, Electrical Engineering, Signal Processing and Biomedical Engineering
Antaros Medical AB
Leona Plum-Mörschel
Profil
Rohit Loomba
University of California at San Diego (UCSD)
Alimentary Pharmacology and Therapeutics
0269-2813 (ISSN) 13652036 (eISSN)
Vol. 54 11-12 1498-1498Subject Categories
Cell and Molecular Biology
Gastroenterology and Hepatology
Cardiac and Cardiovascular Systems
DOI
10.1111/apt.16669
PubMed
34741327